SCHEMBL19207970

SCHEMBL19207970

COC(=O)c1n[nH]cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
KDM4C Q9H3R0 1/20 0.43
KDM4E B2RXH2 6/20 0.42
STAT3 P40763 1/20 0.42
HIF1A Q16665 1/20 0.42
ALPL P05186 3/20 0.41
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 5/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
RAB9A P51151 1/20 0.37
MAP2K4 P45985 1/20 0.37
MAP2K1 Q02750 1/20 0.37
HSD17B10 Q99714 1/20 0.36
NR4A2 P43354 1/20 0.36
CREBBP Q92793 1/20 0.36
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
NFKB1 P19838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1431096 0.79 KDM4E (0.46) NPSR1SMN1; SMN2KDM4EL3MBTL1RAB9A
SCHEMBL19763311 0.78 KDM4C (0.48) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL69295 0.78 NPSR1 (0.48) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL5761874 0.78 NPSR1 (0.48) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL983024 0.76 NPSR1 (0.46) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL19780563 0.76 NPSR1 (0.46) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL546639 0.76 NPSR1 (0.46) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL13726965 0.76 NPSR1 (0.46) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL13606627 0.76 NPSR1 (0.42) NPSR1SMN1; SMN2KDM4CKDM4ESTAT3
SCHEMBL31386708 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 US disclosed
US-20250066360-A1 PYRIDINE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-02-27 US disclosed
CN-119306719-A Salt and crystal form containing pyridine polycyclic derivative, preparation method and application thereof 上海翰森生物医药科技有限公司 2025-01-14 CN disclosed
CN-119306701-A Five-membered ring derivative-containing inhibitor crystal form, preparation method and application thereof 上海翰森生物医药科技有限公司 2025-01-14 CN disclosed
CN-118994190-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 CN disclosed
CN-118994191-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 CN disclosed
EP-4464694-A1 PYRIDINE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-11-20 EP disclosed
CN-114437105-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-10-11 CN disclosed
EP-4426681-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2024-09-11 EP disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 US disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 US disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 WO disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 WO disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 NPSR1 2688/4885SMN1; SMN2 2572/4885KDM4C 921/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB NPSR1 4297/4885SMN1; SMN2 2486/4885KDM4C 1422/4885
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB NPSR1 4297/4885SMN1; SMN2 2486/4885KDM4C 1422/4885
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB NPSR1 4297/4885SMN1; SMN2 2486/4885KDM4C 1422/4885
US-20250066360-A1 PYRIDINE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF MYD88, NOD1, LITAF NPSR1 3779/4885SMN1; SMN2 4849/4885KDM4C 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.